{
  "docId": "019de070-701b-7388-a208-3e38cd293d9a",
  "docSlug": "f771dd63c4f3642a1d968d8585ded9c7",
  "documentTitle": "Evotec | Investor Day Presentation Deck | 103 slides",
  "authorId": "evotec",
  "authorName": "Evotec",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 103,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 45,
  "notes": "The slide presents three line charts showing dose-response curves for EVT895 (labeled Abk77) versus Pegasys.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-701b-7388-a208-3e38cd293d9a/32",
  "deckHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a",
  "deckJsonHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a.json",
  "deckAnchorHref": "/decks/019de070-701b-7388-a208-3e38cd293d9a#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.971,
        "x": 0.028,
        "y": 0.796
      },
      "kind": "callout",
      "text": "Late pre-clinical development; Phase I in 2021 (e)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d44ee4cf-6f9b-4283-b968-9739ac77a094",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.312,
        "x": 0.673,
        "y": 0.392
      },
      "kind": "chart",
      "text": "Hbe release: Comparison with Pegasys (donor 2)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "129d6cb1-8b6a-4624-82ec-dd8771a84e83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.312,
        "x": 0.356,
        "y": 0.392
      },
      "kind": "chart",
      "text": "CD40 agonism compared to CD40 agonistic antibody",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e228b78-0dc5-4e4d-bc1b-962a4343d16e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.335,
        "w": 0.312,
        "x": 0.039,
        "y": 0.392
      },
      "kind": "chart",
      "text": "Interferon pathway stimulation compared to Pegasys",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4159e99e-8ef3-4303-9820-092c93677e87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.455,
        "x": 0.256,
        "y": 0.184
      },
      "kind": "paragraph",
      "text": "EVT895: A potent biologics antiviral - Bifunctional molecule",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c29d3ed-ee74-4262-a90d-d01e90283fec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.032,
        "w": 0.515,
        "x": 0.256,
        "y": 0.114
      },
      "kind": "title",
      "text": "Stimulate interferon pathway and agonise CD40",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c369532-189c-4b08-8612-c7255240c84d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Visual Anchors",
      "slug": "visual-anchors",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "81657864-6c57-495f-a177-189767ccd974",
      "evidence": "The slide uses charts and graphs (e.g., Interferon pathway stimulation compared to Pegasys) as visual anchors to help the audience understand complex data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 50,
      "from": 31,
      "beatId": "26c91166-5be4-427d-a9a5-7b1df4f144e6",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The deck outlines Evotec's approach to precision medicine and co-owned clinical pipeline.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}